A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
Allogeneic Stem Cell Transplantation for Patients Age >= 70 Years with Myelodysplastic Syndrome: A Retrospective Study of the MDS Subcommittee of the Chronic Malignancies Working Party of the EBMT
Silke Heidenreich,Dimitris Ziagkos,Liesbeth C. de Wreede,Anja van Biezen,Jürgen Finke,Uwe Platzbecker,Dietger Niederwieser,Hermann Einsele,Wolfgang Bethge,Michael Schleuning,Dietrich W. Beelen,Johanna Tischer,Arnon Nagler,Bertram Glass,Johan Maertens,Lucrecia Yáñez,Yves Beguin,Heinz Sill,Christof Scheid,Matthias Stelljes,Arnold Ganser,Pierre Zachee,Dominik Selleslag,Theo de Witte,Marie Robin,Nicolaus Kröger +25 more
TL;DR: After careful patient selection, allogeneic HSCT can be offered to patients older than 70 years with MDS, and good performance, determined by Karnofsky performance status, and recipients' seronegativity for cytomegalovirus was associated with 3-year estimated overall survival rates.
Journal ArticleDOI
Autologous transplant remains the preferred therapy for relapsed APL in CR2
Chezi Ganzel,Vikram Mathews,Kamran Alimoghaddam,A. Ghavamzadeh,Deborah Kuk,Sean M. Devlin,Hai-Lin Wang,Mei-Jie Zhang,Daniel J. Weisdorf,Dan Douer,Jacob M. Rowe,Jacob M. Rowe,E. Polge,Jordi Esteve,Arnon Nagler,M. Mohty,Martin S. Tallman +16 more
TL;DR: It is suggested that auto-HCT for APL patients in CR2 results in better OS than ATO-based therapy alone, and is associated with longer duration of CR1, but not with disease risk at diagnosis.
Journal ArticleDOI
Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning : a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation
Avichai Shimoni,Myriam Labopin,Bipin N. Savani,Liisa Volin,Gerhard Ehninger,Jürgen Kuball,Donald Bunjes,Nicolaas Schaap,Stephane Vigouroux,Andrea Bacigalupo,Hendrik Veelken,Jorge Sierra,Matthias Eder,Dietger Niederwieser,Mohamad Mohty,Arnon Nagler +15 more
TL;DR: In this article, the authors analyzed long-term outcomes in a cohort of 1423 AML patients, age ≥ 50 years, after SCT from HLA-matched siblings, during the years 1997-2005, median follow-up 8.3 years (0.1-17) and 10-year leukemia-free survival (LFS) was 31% (95CI, 27-35, and 32% (28-35) after MAC and RIC, respectively (P
Journal ArticleDOI
Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis
Stefania Oliva,M.T. Petrucci,Vittorio Montefusco,Concetta Conticello,Pellegrino Musto,Lucio Catalano,Andrea Evangelista,Stefano Spada,Philip Campbell,Roberto Ria,Marco Salvini,Massimo Offidani,A. M. Carella,Paola Omedè,Anna Marina Liberati,Rosella Troia,A. M. Cafro,Alessandra Malfitano,A. Falcone,Tommaso Caravita,Francesca Patriarca,Arnon Nagler,Andrew Spencer,Roman Hájek,Antonio Palumbo,Mario Boccadoro +25 more
TL;DR: The role of upfront ASCT as the standard approach for all young myeloma patients is confirmed, and the impact of salvage ASCT at first relapse in patients who received upfront CC+R is still effectively rescued.
Journal ArticleDOI
Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: long-term follow-up.
TL;DR: Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning and long-term follow-up shows promising results.